Related Experiment Video

Updated: Aug 12, 2026

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells
06:55

Measurement of Natural Killer Cell-Mediated Cytotoxicity and Migration in the Context of Hepatic Tumor Cells

Published on: February 22, 2020

Tumor-specific targeting of a cell line with natural killer cell activity by asialoglycoprotein receptor gene

T Schirrmann1, G Pecher

  • 1Humboldt-University Berlin, Medical Clinic II-Oncology and Hematology, Germany.

Cancer Immunology, Immunotherapy : CII
|January 5, 2002
PubMed

Insights

Researchers engineered natural killer (NK) cells to target tumors by introducing the asialoglycoprotein receptor (ASGPR). This modification enhanced NK cell binding and killing of cancer cells, offering a promising immunotherapy approach.

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • Adoptive immunotherapy relies on specific targeting of effector cells to tumor cells.
  • Enhancing effector cell specificity and numbers is crucial for successful cancer treatment.

Purpose of the Study:

  • To engineer the human natural killer (NK) cell line YT for specific targeting of tumor cells.
  • To investigate the potential of the asialoglycoprotein receptor (ASGPR) for tumor cell recognition.

Main Methods:

  • Transfection of YT cells with the cDNA of human asialoglycoprotein receptor (ASGPR).
  • Binding assays to evaluate the interaction between modified YT cells and tumor cell lines.
  • Assessment of cytolytic activity of engineered YT cells against various cancer cell lines.

Main Results:

  • ASGPR-gene-transfected YT cells demonstrated significantly higher binding to tested tumor cell lines compared to control cells.
  • Enhanced cytolytic activity was observed against Raji, Jurkat, and TF-antigen-positive KG1 tumor cells.
  • The Thomsen-Friedenreich (TF) antigen, recognized by ASGPR, is present on tumor cells.

Conclusions:

  • Genetic modification of YT cells with ASGPR enables specific tumor cell targeting.
  • Engineered NK cells show potential as a valuable tool for adoptive immunotherapy.
  • This approach could improve the efficacy of cancer treatment by enhancing immune cell-mediated tumor destruction.

More Related Videos

Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line11:02

Natural Killer (NK) and CAR-NK Cell Expansion Method using Membrane Bound-IL-21-Modified B Cell Line

Published on: February 8, 2022

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.